Canadian biopharmaceutical firm Aeterna Zentaris has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for its ghrelin agonist, macimorelin acetate (AEZS-130), a novel orally-active small molecule. The ...
Tags: Aeterna Zentaris, Medicine
Aeterna Zentaris has transferred manufacturing license for its Cetrotide (cetrorelix acetate for injection) product to German-based Merck Serono. Cetrotide is used in women undergoing infertility treatment for the regulation of hormone ...
Tags: Aeterna, Merck Serono, Medicine
Aeterna Zentaris has signed a co-development and profit sharing agreement with Ergomed Clinical Research for AEZS-108 in endometrial cancer. Ergomed has been selected as the contract clinical development organization to conduct the Phase ...
The US Patent and Trademark Office (USPTO) has granted a patent for the use of Aeterna Zentaris' oral ghrelin agonist, AEZS-130 (EP1572) as a diagnostic test for adult growth hormone deficiency (AGHD). AEZS-130, which has been granted ...
Tags: AEZS-130, growth hormone deficiency, AGHD